Akari Therapeutics (AKTX) Enterprise Value (QoQ) (2014 - 2026)
Akari Therapeutics (AKTX) Enterprise Value (QoQ) (2014 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Genmab A | 276,399.99 Bn | 276,398.47 Bn | 831.00 Mn |
| 2 | Akari Therapeutics | 1,217.26 Bn | 1,217.26 Bn | - |
| 3 | BeOne Medicines | 419.38 Bn | 414.59 Bn | 1.35 Bn |
| 4 | Vertex Pharmaceuticals | 126.54 Bn | 119.30 Bn | 2.59 Bn |
| 5 | Pharming | 110.17 Bn | 110.12 Bn | 65.80 Mn |
| 6 | Regeneron Pharmaceuticals | 64.97 Bn | 56.22 Bn | 3.31 Bn |
| 7 | Argenx Se | 56.44 Bn | 56.44 Bn | 1.18 Bn |
| 8 | Alnylam Pharmaceuticals | 40.09 Bn | 37.08 Bn | 959.66 Mn |
| 9 | Revolution Medicines | 37.15 Bn | 37.15 Bn | - |
| 10 | Moderna | 28.64 Bn | 23.43 Bn | -566.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 46.80% |
| Dec 31, 2025 | -3,100.53% |
| Sep 30, 2025 | 94.00% |
| Jun 30, 2025 | -2.61% |
| Mar 31, 2025 | 0.64% |
| Dec 31, 2024 | -18.39% |
| Sep 30, 2024 | 46.23% |
| Jun 30, 2024 | -218.85% |
| Mar 31, 2024 | 65.93% |
| Sep 30, 2020 | 3.36% |
| Dec 31, 2019 | 8.57% |
| Sep 30, 2019 | -129.06% |
| Mar 31, 2016 | 10.87% |
| Dec 31, 2015 | 12.51% |
| Mar 31, 2015 | 60.07% |
| Dec 31, 2014 | -6,224.30% |
| Mar 31, 2014 | -2,397.59% |